23andme reaches agreement for sale of business to ttam research institute following final round of bidding in court-approved sale process

Ttam commits to comply with company's privacy policy and all applicable laws ttam commits to adopting additional consumer protections and privacy safeguards to enhance protections for customer data and privacy no changes to 23andme's privacy policy or consumer genome services transaction subject to court approval san francisco, june 13, 2025 (globe newswire) -- 23andme holding co. (“23andme” or the “company”) (otc: mehcq), a leading human genetics and biotechnology company, today announced that it has entered into a definitive agreement with ttam research institute (“ttam”), a nonprofit public benefit corporation based in california and led by 23andme co-founder and former ceo anne wojcicki, for the sale of substantially all of the company's assets, including the personal genome service (pgs) and research services business lines and the lemonaid health business, for a purchase price of $305 million. the agreement with ttam is the result of a final round of bidding that occurred earlier today between ttam and regeneron pharmaceuticals, inc. (“regeneron”) (nasdaq: regn).
REGN Ratings Summary
REGN Quant Ranking